Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Erlotinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 15/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 4/20 | 1.00 |
| ▸ | GAK | O14976 | 3/20 | 0.98 |
| ▸ | ILK | Q13418 | 3/20 | 0.98 |
| ▸ | FLT1 | P17948 | 2/20 | 0.98 |
| ▸ | KDR | P35968 | 2/20 | 0.98 |
| ▸ | PLK4 | O00444 | 1/20 | 0.98 |
| ▸ | CIT | O14578 | 1/20 | 0.98 |
| ▸ | AURKA | O14965 | 1/20 | 0.98 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.98 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.98 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.98 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.98 |
| ▸ | BUB1 | O43683 | 1/20 | 0.98 |
| ▸ | KDM1A | O60341 | 1/20 | 0.98 |
| ▸ | JAK2 | O60674 | 1/20 | 0.98 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.98 |
| ▸ | STK17B | O94768 | 1/20 | 0.98 |
| ▸ | STK10 | O94804 | 1/20 | 0.98 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Erlotinib SCHEMBL18563 | 1.00 | EGFR (1.00) | EGFRERBB2GAKILKFLT1 | |
| Erlotinib SCHEMBL21176918 | 1.00 | EGFR (1.00) | EGFRERBB2GAKILKFLT1 | |
| Erlotinib SCHEMBL16767632 | 1.00 | EGFR (1.00) | EGFRERBB2GAKILKFLT1 | |
| Erlotinib SCHEMBL3826918 | 0.99 | EGFR (0.98) | EGFRERBB2GAKILKFLT1 | |
| Erlotinib SCHEMBL1759094 | 0.99 | EGFR (0.98) | EGFRERBB2GAKILKFLT1 | |
| Erlotinib SCHEMBL29351329 | 0.99 | EGFR (1.00) | EGFRERBB2GAKILKFLT1 | |
| Erlotinib SCHEMBL30362833 | 0.99 | EGFR (1.00) | EGFRERBB2GAKILKFLT1 | |
| Erlotinib SCHEMBL8413 | 0.99 | EGFR (1.00) | EGFRERBB2GAKILKFLT1 | |
| Erlotinib SCHEMBL3667407 | 0.99 | EGFR (1.00) | EGFRERBB2GAKILKFLT1 | |
| Erlotinib SCHEMBL1959332 | 0.98 | EGFR (0.98) | EGFRERBB2GAKILKFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| US-20230190748-A1 | COMPOSITIONS FOR TREATMENT OF AGED DISEASES | GERO PTE LTD (SG) | 2023-06-22 | — | — | US | claimed |
| CN-122028918-A | TRIM7 inhibitors and uses thereof | 沙塔克实验室有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20250276066-A1 | METHODS, COMPOSITIONS AND COMPOUNDS FOR TREATING AGE-RELATED DISEASES AND CONDITIONS | GERO PTE LTD (SG) | 2025-09-04 | — | — | US | disclosed |
| CN-120025279-A | Compounds capable of modulating endoplasmic reticulum aminopeptidase 1 | 格雷沃尔夫治疗有限公司 | 2025-05-23 | — | — | CN | disclosed |
| CN-113382750-B | CDCP1 targeted therapy | 贝斯以色列女执事医疗中心 | 2025-05-09 | — | — | CN | disclosed |
| CN-113767115-B | Therapeutic interferon alpha 1 proteins | 奥里尼斯生物科学股份有限公司 | 2025-05-02 | — | — | CN | disclosed |
| CN-119836305-A | Antibody-drug conjugates | 费恩治疗有限公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-119836306-A | Antibody drug conjugates that bind CDCP1 and uses thereof | 费恩治疗有限公司 | 2025-04-15 | — | — | CN | disclosed |
| CN-119285770-A | PD-1 and PD-L1 binding agents | 奥里尼斯生物科学有限公司 | 2025-01-10 | — | — | CN | disclosed |
| CN-118994414-A | Chimeric proteins based on TIGIT and LIGHT | 沙塔克实验室有限公司 | 2024-11-22 | — | — | CN | disclosed |
| US-20230190748-A1 | COMPOSITIONS FOR TREATMENT OF AGED DISEASES | GERO PTE LTD (SG) | 2023-06-22 | — | — | US | disclosed |
| US-20230172986-A1 | TREATMENT AND PREVENTION OF ALLOREACTIVITY USING VIRUS-SPECIFIC IMMUNE CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTORS | BAYLOR COLLEGE OF MEDICINE | 2023-06-08 | — | — | US | disclosed |
| US-20230167187-A1 | VIRUS-SPECIFIC IMMUNE CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTORS | BAYLOR COLLEGE OF MEDICINE | 2023-06-01 | — | — | US | disclosed |
| EP-4142750-A1 | TREATMENT AND PREVENTION OF ALLOREACTIVITY USING VIRUS-SPECIFIC IMMUNE CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTORS | Baylor College of Medicine (US) | 2023-03-08 | — | — | EP | disclosed |
| CN-110891947-B | Process for preparing ailutinib or a pharmaceutically acceptable salt thereof | 北京费森尤斯卡比医药有限公司 | 2022-11-25 | — | — | CN | disclosed |
| US-20220235014-A1 | PROCESS FOR THE PREPARATION OF HIGHLY PURE ERLOTINIB HYDROCHLORIDE | SHIVALIK RASAYAN LIMITED (IN) | 2022-07-28 | — | — | US | disclosed |
| EP-4025251-A1 | METHODS OF TREATMENT USING A GENETICALLY MODIFIED AUTOLOGOUS T-CELL IMMUNOTHERAPY | PACT Pharma, Inc. (US) | 2022-07-13 | — | — | EP | disclosed |
| CN-114514035-A | Compositions and methods for delivering therapeutic biologies for treatment of diseases | 伊勒卓菲公司 | 2022-05-17 | — | — | CN | disclosed |
| WO-2022061094-A1 | SOLID DOSAGE FORMS OF BACTERIA | EVELO BIOSCIENCES, INC. (US) | 2022-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230190748-A1 | COMPOSITIONS FOR TREATMENT OF AGED DISEASES | AGER, CKMT1A; CKMT1B, GLA | EGFR 1153/4885ERBB2 1599/4885GAK 754/4885 |
| US-20220235014-A1 | PROCESS FOR THE PREPARATION OF HIGHLY PURE ERLOTINIB HYDROCHLORIDE | EGFR, KRAS, ERBB4 | EGFR 1/4885ERBB2 4/4885GAK 3026/4885 |
| US-20250276066-A1 | METHODS, COMPOSITIONS AND COMPOUNDS FOR TREATING AGE-RELATED DISEASES AND CONDITIONS | UPF1, NLN, BRCA1 | EGFR 2276/4885ERBB2 3331/4885GAK 1885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.